Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Evotaz (atazanavir/cobicistat) and Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are both antiretroviral medications used to treat HIV. They both contain cobicistat, which acts as a "booster" to enhance the effectiveness of other components. However, they differ in their composition and specific roles in HIV treatment. Evotaz combines atazanavir, a protease inhibitor, with cobicistat and must be taken with other HIV medications, as it is not a complete regimen on its own. In contrast, Genvoya is a complete regimen that includes elvitegravir, an integrase strand transfer inhibitor, along with two nucleoside reverse transcriptase inhibitors (NRTIs), emtricitabine and tenofovir alafenamide. Both medications are only available in a branded version. Common side effects of Evotaz include jaundice and rash, whereas Genvoya may cause nausea and diarrhea. Both medications have significant drug interactions, but Genvoya specifically warns against use with certain medications like carbamazepine and lovastatin. Neither medication is recommended during pregnancy.
Evotaz (atazanavir / cobicistat)
Genvoya
Evotaz (atazanavir / cobicistat)
Genvoya
Summary of Evotaz vs. Genvoya
Summary for Antiretroviral
Prescription only
Evotaz (atazanavir / cobicistat) is a combination medication that's taken as part of an antiretroviral (ARV) regimen to treat HIV (human immunodeficiency virus). It's approved for people with HIV who weigh at least 77 pounds. Evotaz (atazanavir / cobicistat) is a tablet that's taken once a day with food. It must be taken along with other HIV ARV medications. Evotaz (atazanavir / cobicistat) can cause side effects, including rash and jaundice (yellowing of the skin or eyes).